ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1614

Factors Associated with Peripheral Neuropathies in Patients with Systemic Lupus Erythematosus: A Single Center Experience

Gabriela Garcia-Guevara1, Francisco Treviño-Tello 2, Christopher Cabib 1, Irazú Contreras-Yáñez 3, Erwin Chiquete 4, Ariadna Díaz-Mora 1, Yuliana Fernandez-Nicoli 4, Julio Macias-Gallardo 5, Juan José Gómez-Piña 4, Ivonne Sandoval-Flores 4 and Hilda Fragoso-Loyo 6, 1Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico, 2Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, 3Instituto Nacional de Ciencias Médicas y Nutrición "Salvador Zubirán", Mexico City, Distrito Federal, Mexico, 4Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico, Mexico, 5Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico, 6Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: Lupus and neuropathy

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 11, 2019

Title: SLE – Clinical Poster II: Comorbidities

Session Type: Poster Session (Monday)

Session Time: 9:00AM-11:00AM

Background/Purpose: The prevalence of peripheral neurological manifestations in Systemic Lupus Erythematosus (SLE) ranges between 1.5% and 27% and are a major cause of morbidity.
To determine associated factors with the different neurophysiological patterns in peripheral neuropathies in patients with systemic lupus erythematosus.

Methods: A retrospective study was performed. We included patients with SLE (ACR 1997 and SLICC 2012 criteria), who presented a PNP associated with SLE according to ACR 1999 nomenclature, from January 2014 to December 2018. Patients were classified according to the neurophysiologic pattern by the Neuromuscular Clinic Disorders at our Institute in 3 groups: 1. Sensory or sensory-motor axonal neuropathy (ANP). 2. Multiplex Mononeuropathy (MNP), and 3. Demyelinating neuropathy (DNP). Clinical information including demographics and SLE characteristics were gathered from the clinical chart and reviewed by an expert rheumatologist in three different moments: Previous visit (3 months before to PNP presentation); at the time of PNP presentation, and one year after. Demographic characteristics: gender, age, Body Mass Index (BMI), and comorbidities. Lupus characteristics: ACR criteria, the time between SLE diagnosis and PNP presentation, ACR / 2012   criteria, disease activity (SLEDAI-2K), cumulative damage (ACR/SLICC-DI), and treatment were compared. One year after, disease activity, cumulative damage, and treatment were reviewed. Statistical analysis: Mann-Whitney U, Chi-squared test and Fisher exact test were used as appropriate. Multiple comparisons and logistic regression analysis was made.

Results: Ninety one PNP were included, 45 (49.5%) ANP, 17 (18.9%) MNP, and 20 (21.9%) DNP. Demographics and comorbidities were similar between groups. At previous visit, the (SLICC/SDI) was higher in APN group compared with MNP and DNP (table 1). Patients with DNP presented more frequently cutaneous manifestations (alopecia) compared with MNP and ANP (table1). Patients with MNP had more nephropathy compared with ANP and DNP, and patients with APN had more hemolytic anemia compared with other groups (table 1).

 At the time of PNP presentation, patients with ANP were older and had a long time between SLE diagnosis and the PNP presentation, compared with MNP and with DNP (table 1). Patients with MNP had higher disease activity compared with ANP and DNP groups (table 1). Pulses of methylprednisolone, cyclophosphamide, and higher doses of prednisone were used in the MNP compared with DNP and ANP group (p < 0.05). One year after, disease activity and cumulative damage were similar between groups. In the logistic regression analyses, older age, the time between SLE diagnosis and PNP presentation, and cumulative damage in the previous visit were factors independently associated with APN compared with MNP and DNP (table 2).

Conclusion: ANP was the most frequent PNP. Patients with MNP have more disease activity than the other groups.  MNP and DNP considered more severe and received more aggressive treatment than APN. Factors independently associated with APN were older age, have a longer time between SLE diagnosis and the PNP presentation and have more damage 3 months previous the PNP presentation.


Table 1 PNP


Table 2 PNP


Disclosure: G. Garcia-Guevara, None; F. Treviño-Tello, None; C. Cabib, None; I. Contreras-Yáñez, None; E. Chiquete, None; A. Díaz-Mora, None; Y. Fernandez-Nicoli, None; J. Macias-Gallardo, None; J. Gómez-Piña, None; I. Sandoval-Flores, None; H. Fragoso-Loyo, None.

To cite this abstract in AMA style:

Garcia-Guevara G, Treviño-Tello F, Cabib C, Contreras-Yáñez I, Chiquete E, Díaz-Mora A, Fernandez-Nicoli Y, Macias-Gallardo J, Gómez-Piña J, Sandoval-Flores I, Fragoso-Loyo H. Factors Associated with Peripheral Neuropathies in Patients with Systemic Lupus Erythematosus: A Single Center Experience [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/factors-associated-with-peripheral-neuropathies-in-patients-with-systemic-lupus-erythematosus-a-single-center-experience/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/factors-associated-with-peripheral-neuropathies-in-patients-with-systemic-lupus-erythematosus-a-single-center-experience/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology